GRANULES INDIA LIMITED

Manufactures and sells generic pharmaceutical finished dosage formulations (tablets, capsules and other oral solids), which made up 74% of consolidated revenue in Q1 FY27. The complex-generics portion of the finished-dosage book has risen to 50% (from 39% a year earlier), and the company now holds two Sole First-to-File ANDA approvals that grant 180-day US market exclusivity — Sodium Oxybate Extended-Release Oral Suspension (generic of LUMRYZ for narcolepsy) and Amphetamine Extended-Release Tablets. Alongside finished dosages, it makes Active Pharmaceutical Ingredients (13% of Q1 FY27 revenue), Pharma Formulation Intermediates (9%), and runs a peptide Contract Development and Manufacturing Organization through the acquired Senn Chemicals AG, which grew more than 100% year-on-year and contributed 4% of revenue. Manufacturing spans eight facilities; seven have a clean Establishment Inspection Report from the USFDA, with 9 product launches and 25 ANDAs sitting behind the Gagillapur facility's pending reinspection. R&D spending ran at about 6% of sales in Q1 FY27, and FY27 capex is guided at ₹600 crore, including roughly ₹300 crore phased over multiple years for a peptide intermediates and API plant in India.